Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology – Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) announced its participation in the upcoming Society of Forensic Toxicologists (SOFT) conference in October. Dr. Bruce Goldberger, Senior Advisor to Cannabix, will present the company's marijuana breathalyzer system at a workshop session titled 'Chasing Impairment – Advancement in Technologies or a Paradigm Shift? – You be the Judge!'
In collaboration with Omega Laboratories Inc., Cannabix has upgraded its Breath Collection Unit with new features to meet market and regulatory requirements. These include an 'on demand' quality assurance check, a startup self-check, and a new ambient air sample collection procedure. The sample collection cartridge has been modified to collect single or dual samples.
Omega scientists have successfully detected and quantified delta-9 THC in the low picogram range using Cannabix's technology. They have also developed a test method that detects, isolates, and quantifies delta-9 THC, delta-8 THC, CBN, and CBD from breath samples. The partnership aims to advance the development and commercialization of Cannabix's marijuana breathalyzer technology.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) ha annunciato la sua partecipazione alla prossima conferenza della Society of Forensic Toxicologists (SOFT) che si terrà in ottobre. Il Dr. Bruce Goldberger, Consulente Senior di Cannabix, presenterà il sistema di analisi dell'alito per marijuana dell'azienda durante una sessione del workshop intitolata 'Inseguire l'Impairment – Progresso nelle Tecnologie o un Cambio di Paradigma? – Giudicate voi!'
In collaborazione con Omega Laboratories Inc., Cannabix ha aggiornato la sua Unità di Raccolta dell'Alito con nuove funzionalità per soddisfare i requisiti di mercato e normativi. Queste includono un controllo di qualità 'su richiesta', un'autocontrollo all'avvio e una nuova procedura per la raccolta di campioni di aria ambientale. La cartuccia di raccolta dei campioni è stata modificata per raccogliere campioni singoli o doppi.
Gli scienziati di Omega hanno rilevato e quantificato con successo il delta-9 THC nel range dei picogrammi bassi utilizzando la tecnologia di Cannabix. Hanno anche sviluppato un metodo di test che rileva, isola e quantifica delta-9 THC, delta-8 THC, CBN e CBD dai campioni di alito. La partnership mira a promuovere lo sviluppo e la commercializzazione della tecnologia del Breathalyzer per marijuana di Cannabix.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) anunció su participación en la próxima conferencia de la Society of Forensic Toxicologists (SOFT) en octubre. El Dr. Bruce Goldberger, Asesor Principal de Cannabix, presentará el sistema de alcoholímetro de marihuana de la empresa en una sesión de taller titulada 'Persiguiendo la Impairment – ¿Avance en Tecnologías o un Cambio de Paradigma? – ¡Ustedes deciden!'
En colaboración con Omega Laboratories Inc., Cannabix ha actualizado su Unidad de Recolección de Aliento con nuevas características para cumplir con los requisitos del mercado y regulatorios. Estas incluyen un control de calidad 'a demanda', una auto-verificación al inicio y un nuevo procedimiento para la recolección de muestras de aire ambiental. El cartucho de recolección de muestras ha sido modificado para recolectar muestras individuales o dobles.
Los científicos de Omega han detectado y cuantificado con éxito delta-9 THC en el rango de picogramos bajos utilizando la tecnología de Cannabix. También han desarrollado un método de prueba que detecta, aísla y cuantifica delta-9 THC, delta-8 THC, CBN y CBD a partir de muestras de aliento. La asociación tiene como objetivo avanzar en el desarrollo y comercialización de la tecnología del alcoholímetro de marihuana de Cannabix.
캐너빅스 테크놀로지스 Inc. (CSE: BLO) (OTC PINK: BLOZF)는 10월에 열리는 법의학 독성학회(SOFT) 컨퍼런스에 참여한다고 발표했습니다. 캐너빅스의 고급 고문인 브루스 골드버거 박사는 '장애물 추적 – 기술 발전인가 패러다임 변화인가? – 여러분이 판단하세요!'라는 제목의 워크숍 세션에서 회사의 마리화나 호흡 분석기 시스템을 발표할 예정입니다.
오메가 연구소 Inc.와 협력하여, 캐너빅스는 시장 및 규제 요건을 충족하기 위해 호흡 샘플 수집 장치를 새로운 기능으로 업그레이드했습니다. 여기에는 '온디맨드' 품질 보증 점검, 시작시 자체 점검 및 새로운 주변 공기 샘플 수집 절차가 포함됩니다. 샘플 수집 카트리지는 단일 샘플 또는 이중 샘플을 수집하도록 수정되었습니다.
오메가 과학자들은 캐너빅스 기술을 사용하여 저 피코그램 범위에서 델타-9 THC를 성공적으로 감지하고 정량화했습니다. 그들은 또한 호흡 샘플에서 델타-9 THC, 델타-8 THC, CBN 및 CBD를 감지하고 분리하여 정량화하는 테스트 방법을 개발했습니다. 이 파트너십의 목표는 캐너빅스의 마리화나 호흡 분석기 기술의 개발 및 상용화를 추진하는 것입니다.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) a annoncé sa participation à la prochaine conférence de la Society of Forensic Toxicologists (SOFT) qui se tiendra en octobre. Le Dr Bruce Goldberger, conseiller senior de Cannabix, présentera le système de dépistage de la marijuana de l'entreprise lors d'une session d'atelier intitulée 'Poursuivre l'Impairment – Progrès technologiques ou changement de paradigme ? – À vous de juger !'
En collaboration avec Omega Laboratories Inc., Cannabix a mis à jour son Unité de Collecte de Souffle avec de nouvelles fonctionnalités pour satisfaire aux exigences du marché et réglementaires. Cela comprend un contrôle qualité 'à la demande', une auto-vérification au démarrage et une nouvelle procédure de collecte d'échantillons d'air ambiant. La cartouche de collecte des échantillons a été modifiée pour collecter des échantillons uniques ou doubles.
Les scientifiques d'Omega ont réussi à détecter et à quantifier le delta-9 THC dans la plage des picogrammes faibles en utilisant la technologie de Cannabix. Ils ont également développé une méthode de test qui détecte, isole et quantifie le delta-9 THC, le delta-8 THC, le CBN et le CBD à partir des échantillons de souffle. Le partenariat vise à faire progresser le développement et la commercialisation de la technologie de dépistage de marijuana de Cannabix.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) hat seine Teilnahme an der bevorstehenden Konferenz der Society of Forensic Toxicologists (SOFT) im Oktober angekündigt. Dr. Bruce Goldberger, Senior Advisor von Cannabix, wird das Atemalkoholmessgerät des Unternehmens in einer Workshop-Sitzung mit dem Titel 'Beeinträchtigung verfolgen – Fortschritt in Technologien oder ein Paradigmenwechsel? – Sie haben das Wort!' präsentieren.
In Zusammenarbeit mit Omega Laboratories Inc. hat Cannabix seine Atemprobenahmeeinheit mit neuen Funktionen aufgerüstet, um den Markt- und regulatorischen Anforderungen gerecht zu werden. Dazu gehören ein 'Bedarfs'-Qualitätssicherungscheck, eine Selbstprüfung beim Start und ein neues Verfahren zur Sammlung von Umgebungs-Luftproben. Der Probenentnahmekartusche wurde modifiziert, um Einzel- oder Doppelproben zu sammeln.
Die Wissenschaftler von Omega haben erfolgreich Delta-9 THC im niedrigen Pikogramm-Bereich mithilfe der Technologie von Cannabix nachgewiesen und quantifiziert. Sie haben auch eine Testmethode entwickelt, die Delta-9 THC, Delta-8 THC, CBN und CBD aus Atemproben nachweist, isoliert und quantifiziert. Die Partnerschaft zielt darauf ab, die Entwicklung und Kommerzialisierung der Atemalkoholtechnologie von Cannabix voranzutreiben.
- None.
- None.
VANCOUVER, British Columbia, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) reports that it will be presenting the Company’s marijuana breathalyzer system at the Society of Forensic Toxicologists (SOFT) conference in October in St. Louis. Cannabix Senior Advisor, Dr. Bruce Goldberger (bio below), will be presenting at a conference workshop session titled, “Chasing Impairment – Advancement in Technologies or a Paradigm Shift? – You be the Judge!”. The workshop will explore the latest advancements in the field of drug and impairment testing including cutting-edge techniques for detecting recent cannabis use via breath-based testing protocols.
Furthermore, the Company reports that Omega Laboratories Inc (“Omega Laboratories” or “Omega”) and Cannabix have incorporated several new features to the Company’s marijuana breathalyzer technology to meet market and emerging regulatory requirements. In particular, Cannabix has upgraded its Breath Collection Unit – handheld technology to include an “on demand” periodic quality assurance check, a new startup self check and new ambient air sample collection procedure. The sample collection cartridge has been modified to be able to collect a single sample or dual sample consistent with Federally regulated programs that require a simultaneous A, B sample collection. These additional features have been added in collaboration with Omega. Cannabix and Omega are actively working together to set limits of detection (LOD) and limits of quantification (LOQ) as well as the cutoff level for the detection of delta-9 THC (primary psychoactive ingredient in cannabis) in breath. During spring 2024, Cannabix entered into a strategic partnership and development agreement with Omega Laboratories to advance the development and commercialization of the Cannabix marijuana breathalyzer technology. Omega Laboratories is an international industry leader in forensic drugs of abuse testing with multiple international certifications and accreditations.
Highlights:
- Cannabix engineers have incorporated several new features to the Company’s marijuana breathalyzer technology to meet industry and emerging regulatory requirements.
- Dr. Bruce Goldberger will present the Company’s marijuana breathalyzer system at the Society of Forensic Toxicologists conference in October.
- Thus far, Omega scientists have been able to detect and quantify delta-9 THC in the low picogram range – a level of detection low enough for detecting drug compounds in breath.
- Omega scientists have established a delta-9 THC calibration curve with samples obtained from the Cannabix Breath Collection Unit (BCU) for the purposes of quantification using Omega’s preexisting and well-established extraction and detection processes.
- Omega scientists have consistently detected and quantified delta-9 THC from breath samples collected from subjects utilizing the Cannabix BCU.
- Omega scientists have developed a test method for a breath sample that successfully detects, isolates and quantifies delta-9 THC, delta-8 THC, CBN and CBD. Cannabix and Omega have begun working together on multiple fronts including hardware refinement, marketing and preparing numerous validation studies.
Omega Laboratories is headquartered in Ohio, USA in a state-of-the-art facility providing drugs of abuse testing to over 6,000 clients worldwide, including several Fortune 500 companies, police, highway patrol, court systems, military organizations, and school systems. Omega also has one of the largest Third-Party Administrator (TPA) client lists in America.
About Dr. Bruce Goldberger
Dr. Bruce Goldberger is a professor and the former chief of the Forensic Medicine Division in the Department of Pathology, Immunology and Laboratory Medicine in the College of Medicine at the University of Florida. Dr. Goldberger was the director of the University of Florida forensic toxicology laboratory for approximately 30 years. Dr. Goldberger is the principal investigator of the Florida Drug-Related Outcomes Surveillance and Tracking System (FROST) and Co-investigator of the National Drug Early Warning System (NDEWS).
About Omega Laboratories, Inc.
Omega Laboratories, headquartered in Mogadore, Ohio with an additional state-of-the-art facility in Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 24 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid and Urine. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless online Custody & Control Form system (oCCF) in eight languages, licensure of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers new laboratories in countries that have demand for local service providers.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the primary psychoactive ingredient in cannabis. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of its Breath Logix Series of breath alcohol detection devices for employers and a range of other settings.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with Omega; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
FAQ
What new features has Cannabix added to its marijuana breathalyzer technology?
Who will present Cannabix's marijuana breathalyzer system at the SOFT conference in October?
What level of delta-9 THC detection has Omega Laboratories achieved using Cannabix's technology?
What compounds can Omega's test method detect from breath samples collected using Cannabix's technology?
What is the purpose of Cannabix's partnership with Omega Laboratories?
